David Craven talks about Blackfinch’s shift towards technology, innovation and growth in the EIS space after the Patient Capital Review. He discusses the company’s “aggressive” screening process and the underlying investments in the portfolio. Craven stresses Blackfinch’s commitment to support and mentor investee companies on a more personal level. Looking into the future, he would like to see more cooperation in the EIS world to attract more capital and elevate the UK’s position in the tech space.